These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3741716)

  • 21. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
    Paar WD; Poche S; Gerloff J; Dengler HJ
    Eur J Clin Pharmacol; 1997; 53(3-4):235-9. PubMed ID: 9476037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
    Yoshino H; Hattori Y; Imai H; Narabayashi H; Chiba K
    Rinsho Shinkeigaku; 1993 Mar; 33(3):261-5. PubMed ID: 8334787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.
    Woolhouse NM; Eichelbaum M; Oates NS; Idle JR; Smith RL
    Clin Pharmacol Ther; 1985 May; 37(5):512-21. PubMed ID: 3987174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.
    Clasen K; Madsen L; Brøsen K; Albøge K; Misfeldt S; Gram LF
    Clin Pharmacol Ther; 1991 Jun; 49(6):624-31. PubMed ID: 2060251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
    Brøsen K; Skjelbo E; Flachs H
    Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
    Gram LF; Brøsen K
    Br J Clin Pharmacol; 1993 Jun; 35(6):649-52. PubMed ID: 8329293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.
    Nielsen F; Rosholm JU; Brøsen K
    Eur J Clin Pharmacol; 1995; 48(6):501-4. PubMed ID: 8582470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
    Eichelbaum M; Spannbrucker N; Steincke B; Dengler HJ
    Eur J Clin Pharmacol; 1979 Sep; 16(3):183-7. PubMed ID: 499318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of enzyme induction on polymorphic sparteine oxidation.
    Eichelbaum M; Mineshita S; Ohnhaus EE; Zekorn C
    Br J Clin Pharmacol; 1986 Jul; 22(1):49-53. PubMed ID: 3741726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absence of polymorphism of sparteine oxidation in the South African Venda.
    Sommers DK; Moncrieff J; Avenant JC
    Hum Exp Toxicol; 1991 May; 10(3):175-8. PubMed ID: 1678945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with hyperthyreosis].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Forkasiewicz Z; Dawiskiba J; Bednarz W; Domosławski P
    Endokrynol Pol; 2006; 57(6):605-11. PubMed ID: 17253433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K; Otton SV; Gram LF
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotype of cytochrome P450 CYP2D6 in patients with familial adenomatous polyposis.
    Slanar O; Perlík F; Jirásek V
    Methods Find Exp Clin Pharmacol; 2001 Apr; 23(3):145-7. PubMed ID: 11523314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.
    Horai Y; Ishizaki T; Eichelbaum M; Hashimoto K; Chiba K; Dengler HJ
    Xenobiotica; 1988 Sep; 18(9):1077-84. PubMed ID: 3227705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.
    Nielsen MD; Brøsen K; Gram LF
    Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K; Gram LF
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.